Galena Biopharma and Dr. Reddy's Laboratories Ltd. announced a strategic development and commercialization partnership on NeuVax(TM) (nelipepimut-S) in India. NeuVax(TM) (nelipepimut-S) is the immunodominant nonapeptide derived from the extracellular domain of the HER2 protein, a well-established target for therapeutic intervention in breast carcinoma. The nelipepimut-S sequence stimulates specific CD8+ cytotoxic T lymphocytes following binding to HLA-A2/A3 molecules on antigen presenting cells.